Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis

20081,695 citationsJournal Articlebronze Open Access

Authors

Orlando M. Gutiérrez · Metabolism and Renal Physiology

Michael Mannstadt

Tamara Isakova · Metabolism and Renal Physiology

Jose Alejandro Rauh‐Hain · Metabolism and Renal Physiology

Hector Tamez · Metabolism and Renal Physiology

Anand Shah · Metabolism and Renal Physiology

Kelsey Smith · Metabolism and Renal Physiology

Abstract

Increased FGF-23 levels appear to be independently associated with mortality among patients who are beginning hemodialysis treatment. Future studies might investigate whether FGF-23 is a potential biomarker that can be used to guide strategies for the management of phosphorus balance in patients with chronic kidney disease.

Topics & Keywords

Parathyroid Disorders and Treatments Vitamin D Research Studies Biomedical Research and Pathophysiology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 359, Issue 6, pp. 584-592

DOI: 10.1056/nejmoa0706130

Field-Weighted Citation Impact: 52.05